These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 12590644

  • 1. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.
    Pincelli AI, Rigamonti AE, Scacchi M, Cella SG, Cappa M, Cavagnini F, Müller EE.
    Eur J Endocrinol; 2003 Feb; 148(2):237-43. PubMed ID: 12590644
    [Abstract] [Full Text] [Related]

  • 2. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
    Rigamonti AE, Cavallera G, Bonomo S, Deghenghi R, Locatelli V, Cella SG, Müller EE.
    Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883
    [Abstract] [Full Text] [Related]

  • 4. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
    [Abstract] [Full Text] [Related]

  • 5. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
    Rigamonti AE, Bonomo SM, Cella SG, Müller EE.
    J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
    [Abstract] [Full Text] [Related]

  • 6. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
    Gianotti L, Rolla M, Arvat E, Belliti D, Valetto MR, Ferdeghini M, Ghigo E, Müller EE.
    Biol Psychiatry; 1999 Feb 01; 45(3):334-9. PubMed ID: 10023511
    [Abstract] [Full Text] [Related]

  • 7. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M, Tassone F, Gianotti L, Lanfranco F, Grottoli S, Arvat E, Muller EE, Ghigo E.
    J Clin Endocrinol Metab; 2001 Jan 01; 86(1):167-71. PubMed ID: 11231996
    [Abstract] [Full Text] [Related]

  • 8. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness.
    Gianotti L, Broglio F, Ramunni J, Lanfranco F, Gauna C, Benso A, Zanello M, Arvat E, Ghigo E.
    Eat Weight Disord; 1998 Jun 01; 3(2):64-70. PubMed ID: 10728152
    [Abstract] [Full Text] [Related]

  • 9. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A, South S, Liem AY, Clemmons D, Thorner MO, Weltman A, Veldhuis JD.
    Eur J Endocrinol; 1998 Jul 01; 139(1):59-71. PubMed ID: 9703380
    [Abstract] [Full Text] [Related]

  • 10. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state.
    Broglio F, Gianotti L, Destefanis S, Fassino S, Abbate Daga G, Mondelli V, Lanfranco F, Gottero C, Gauna C, Hofland L, Van der Lely AJ, Ghigo E.
    Clin Endocrinol (Oxf); 2004 May 01; 60(5):592-9. PubMed ID: 15104562
    [Abstract] [Full Text] [Related]

  • 11. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE, Scanniffio D, Bonomo SM, Cella SG, Sartorio A, Müller EE.
    Neuroendocrinology; 2004 May 01; 79(5):237-46. PubMed ID: 15218318
    [Abstract] [Full Text] [Related]

  • 12. Effect of somatostatin infusion on peptide YY secretion: studies in the acute and recovery phase of anorexia nervosa and in obesity.
    Rigamonti AE, Cella SG, Bonomo SM, Mancia G, Grassi G, Perotti M, Agosti F, Sartorio A, Müller EE, Pincelli AI.
    Eur J Endocrinol; 2011 Sep 01; 165(3):421-7. PubMed ID: 21677050
    [Abstract] [Full Text] [Related]

  • 13. Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa.
    Gianotti L, Arvat E, Valetto MR, Ramunni J, Di Vito L, Maccagno B, Camanni F, Ghigo E.
    Biol Psychiatry; 1998 Feb 01; 43(3):181-7. PubMed ID: 9494699
    [Abstract] [Full Text] [Related]

  • 14. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E.
    J Clin Endocrinol Metab; 1997 Jul 01; 82(7):2261-5. PubMed ID: 9215304
    [Abstract] [Full Text] [Related]

  • 15. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb 01; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 16. Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa.
    Gianotti L, Fassino S, Daga GA, Lanfranco F, De Bacco C, Ramunni J, Arvat E, MacCario M, Ghigo E.
    Clin Endocrinol (Oxf); 2000 Jun 01; 52(6):713-20. PubMed ID: 10848875
    [Abstract] [Full Text] [Related]

  • 17. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1995 Dec 01; 43(6):665-9. PubMed ID: 8736266
    [Abstract] [Full Text] [Related]

  • 18. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF, Hindmarsh PC, Brook CG.
    Clin Endocrinol (Oxf); 1997 Nov 01; 47(5):537-47. PubMed ID: 9425393
    [Abstract] [Full Text] [Related]

  • 19. Effect of IGF-I administration on growth hormone secretion in obese subjects.
    Tassone F, Gianotti L, Lanfranco F, Ganzaroli C, Oleandri SE, Taliano M, Muller EE, Ghigo E, Maccario M.
    Int J Obes Relat Metab Disord; 2001 May 01; 25 Suppl 1():S41-2. PubMed ID: 11466586
    [Abstract] [Full Text] [Related]

  • 20. Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation.
    Bondanelli M, Ambrosio MR, Margutti A, Boldrini P, Basaglia N, Franceschetti P, Zatelli MC, Degli Uberti EC.
    Metabolism; 2002 Oct 01; 51(10):1363-9. PubMed ID: 12370860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.